Get ready for some Biogen body language
Among the more charming Wall Street clichés is “body language,” a phrase deployed by analysts when they have to parse noncommittal verbiage from company executives. This morning, when Biogen faces questions on the status of its all-important treatment for Alzheimer’s disease, biotech’s many body language experts will be paying rapt attention.
At 8 a.m. ET, Biogen will host a call to discuss its earnings from the second quarter, a period in which the company finally submitted aducanumab, an oft-delayed Alzheimer’s drug, for FDA approval. It’s unlikely Biogen will say anything new about the application, but you can bet management will be pressed with analystisms about providing “color” and informing how we “should think” about the drug’s potential approval, all in hopes of getting a read on the company's closed-door discussions with regulators.
And it’s easy to understand why. Aducanumab, despite its murky efficacy, could become a multibillion-dollar product if it’s approved. The drug has been sharply divisive for about five years, but its fate still holds profound sway over Biogen’s stock price and corporate future.
At 8 a.m. ET, Biogen will host a call to discuss its earnings from the second quarter, a period in which the company finally submitted aducanumab, an oft-delayed Alzheimer’s drug, for FDA approval. It’s unlikely Biogen will say anything new about the application, but you can bet management will be pressed with analystisms about providing “color” and informing how we “should think” about the drug’s potential approval, all in hopes of getting a read on the company's closed-door discussions with regulators.
And it’s easy to understand why. Aducanumab, despite its murky efficacy, could become a multibillion-dollar product if it’s approved. The drug has been sharply divisive for about five years, but its fate still holds profound sway over Biogen’s stock price and corporate future.
No hay comentarios:
Publicar un comentario